TabletsClinical Overview
Aspirin Gastro-Resistant Tablets (150mg) is an acetylated salicylate on the WHO Model List of Essential Medicines. It irreversibly acetylates the serine 529 residue of cyclooxygenase-1 (COX-1), permanently suppressing platelet thromboxane A2 (TXA2) generation for the entire lifespan of the platelet (7-10 days). Enteric coating bypasses the stomach to dissolve in the alkaline duodenum, minimizing direct contact gastric mucosal injury. Indicated for secondary prevention of myocardial infarction, ischemic stroke, transient ischemic attacks (TIA), and unstable angina.
Active Pharmaceutical Ingredients
Verified Clinical References
Usage Guidelines
Take orally once daily with a full glass of water, with or after meals. Swallow the enteric-coated tablet whole; do NOT crush, split, or chew, as crushing destroys the gastro-protective coating.
General Administration Advice: Adhere strictly to the prescribed dosage, frequency, and treatment course. For oral medications, swallow with sufficient water. Never stop antibiotics, psychiatric medications, or antihypertensives abruptly without clinical direction.
Possible Side Effects
Common: Dyspepsia, heartburn, nausea, increased bleeding tendency, easy bruising. Rare/Severe: Major gastrointestinal hemorrhage, hemorrhagic stroke, bronchospasm (aspirin-induced asthma), and tinnitus (salicylism with high doses).
*Note: Individual physiological responses vary. While many patients experience few or no side effects, notify your treating physician if adverse reactions persist or if hypersensitivity (angioedema, skin rash, dyspnea) occurs.
Precautions & Warnings
Strictly contraindicated in children and adolescents under 16 years of age with viral infections due to fatal Reye's syndrome risk. Contraindicated in active peptic ulcer disease and bleeding disorders. Withhold 7 days prior to elective surgery.
Medical Disclaimer: Statutory Clinical Disclaimer: The information provided is for educational and price-transparency purposes only and does not constitute medical advice, clinical diagnosis, or analgesic treatment guidance. Always consult a registered physician or orthopedic specialist before taking pain relievers, anti-inflammatory medications, or anti-arthritic therapies.
Clopidogrel 75mg + Aspirin 75mg Tablets
Clopidogrel and Aspirin is the cornerstone Dual Antiplatelet Therapy (DAPT) on the WHO Model List of Essential Medicines. Aspirin irreversibly acetylates platelet cyclooxygenase-1 (COX-1), blocking thromboxane A2 production, while clopidogrel is an oral thienopyridine prodrug whose active metabolite irreversibly binds to platelet P2Y12 adenosine diphosphate (ADP) receptors, preventing ADP-mediated glycoprotein IIb/IIIa activation. This dual blockade potently inhibits platelet aggregation across complementary pathways. Indicated for acute coronary syndromes (STEMI, NSTEMI, unstable angina) and prevention of subacute stent thrombosis following percutaneous coronary intervention (PCI).
Acetylsalicylic Acid (Aspirin) Gastro-resistant Tablets 325mg
Acetylsalicylic Acid (Aspirin) Gastro-resistant Tablets 325mg is an evidence-based dermatological formulation. It acts by delivering targeted active therapeutic ingredients to cutaneous lesions to relieve skin pathology, restore barrier integrity, and manage dermatoses.
Aspirin Enteric Coated Tablets 75mg
Aspirin (Acetylsalicylic Acid, low-dose 75 mg - 150 mg) is the prototype antiplatelet agent on the WHO Model List of Essential Medicines. It irreversibly acetylates serine 529 of platelet cyclooxygenase-1 (COX-1), permanently suppressing the synthesis of thromboxane A2 (a potent platelet aggregator and vasoconstrictor) for the 7-10 day lifespan of the platelet. Gastro-resistant (enteric-coated) formulations protect the gastric mucosa by dissolving only in the neutral pH of the small intestine. Indicated for secondary prevention of recurrent myocardial infarction, ischemic stroke, transient ischemic attacks (TIAs), and following coronary bypass or stent placement.
Aspirin Gastro-resistant 75mg + Atorvastatin 10mg Capsules
Statin and Antiplatelet (Aspirin +/- Clopidogrel) cardiovascular polypill formulation. Unites intensive lipid lowering and plaque stabilization (via HMG-CoA reductase inhibition) with antiplatelet thrombus prevention (via irreversible COX-1 inhibition and/or ADP P2Y12 platelet receptor blockade). Indicated for secondary prevention in coronary artery disease, acute coronary syndrome, post-percutaneous coronary intervention (PCI/stenting), and ischemic stroke.